Other drugs, such as coenzyme Q10, rapamycin, and the LRRK2 kinase inhibitor GW5074, were able to rescue cellular vulnerability that was associated with mitochondrial dysfunction in iPSC-derived neural cells from familial PD patients and at-risk individuals [66]. The gene discussed is LRRK2; the disease is Parkinson disease.